文献速递浆细胞疾病

达雷妥尤单抗联合方案治疗复发难治多发性骨髓瘤患者健康相关生活质量长期维持:CASTOR III期试验结果

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
PubMed 文献 · Br J Haematol · 2021-02-08

CASTOR III期试验显示,达雷妥尤单抗联合硼替佐米和地塞米松(D-Vd)较单用硼替佐米和地塞米松(Vd)显著延长复发难治多发性骨髓瘤(RRMM)患者的无进展生存期。本文报告患者报告结局(PROs),采用EORTC QLQ-C30和EQ-5D问卷评估,结果显示前8个周期两组生活质量变化相似且未超过10分,此后长期接受达雷妥尤单抗治疗的患者报告总体健康状况和疼痛改善。

要点

  • D-Vd方案在前8个周期内对健康相关生活质量的影响与Vd方案相似。
  • 长期接受达雷妥尤单抗治疗的患者报告总体健康状况和疼痛改善。
  • PRO评估依从性高且两组间相似,支持D-Vd在RRMM中的应用。

核心结论

  • D-Vd方案在RRMM患者中维持健康相关生活质量,长期治疗可改善总体健康状况和疼痛。

研究设计与样本

  • III期CASTOR试验的患者报告结局分析,使用EORTC QLQ-C30和EQ-5D问卷评估。

主要发现

  • 前8个周期两组EORTC QLQ-C30总体健康状况、功能和症状的平均变化相似,均未超过10分。
  • 亚组分析与总体人群结果一致。
  • 8个周期后,长期接受达雷妥尤单抗治疗的患者报告总体健康状况和疼痛改善。

临床怎么用

  • D-Vd方案在延长无进展生存期的同时不损害生活质量,支持其用于RRMM患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D-Vd) significantly extended progression-free survival compared with bortezomib and dexamethasone (Vd) alone in patients with relapsed/refractory multiple myeloma (RRMM). Here, we present patient-reported outcomes (PROs) from the CASTOR trial. PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system questionnaire. Treatment effects through Cycle 8 were measured by a repeated measures mixed-effects model. After Cycle 8, PROs were only collected for patients in the D-Vd group who continued on daratumumab monotherapy. Compliance rates for PRO assessments were high and similar between treatment groups. Mean changes from baseline were generally similar between treatment groups for EORTC QLQ-C30 global health status (GHS), functioning and symptoms, and did not exceed 10 points for either treatment group. Subgroup analyses were consistent with the results observed in the overall population. There was no change in patients' health-related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long-term reported improvements in GHS and pain. These results complement the significant clinical benefits observed with D-Vd in patients with RRMM and support its use in this patient population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hungria V, Beksac M, Weisel KC, et al. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. Br J Haematol. 2021. PMID: 33555030. doi:10.1111/bjh.17321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。